Purpose Patient-reported outcomes should ideally be adapted to the individual patient while maintaining comparability of scores across patients. This is achievable using computerized adaptive testing (CAT). The aim here was to develop an item bank for CAT measurement of the pain domain as measured by the EORTC QLQ-C30 questionnaire. Methods The development process consisted of four steps: (1) literature search, (2) formulation of new items and expert evaluations, (3) pretesting and (4) field-testing and psychometric analyses for the final selection of items. Results In step 1, we identified 337 pain items from the literature. Twenty-nine new items fitting the QLQ-C30 item style were formulated in step 2 that were reduced to 26 items by expert evaluations. Based on interviews with 31 patients from Denmark, France and the UK, the list was further reduced to 21 items in step 3. In phase 4, responses were obtained from 1103 cancer patients from five countries. Psychometric evaluations showed that 16 items could be retained in a unidimensional item bank. Evaluations indicated that use of the CAT measure may reduce sample size requirements with 15-25 % compared to using the QLQ-C30 pain scale. Conclusions We have established an item bank of 16 items suitable for CAT measurement of pain. While being backward compatible with the QLQ-C30, the new item bank will significantly improve measurement precision of pain. We recommend initiating CAT measurement by screening for pain using the two original QLQ-C30 pain items. The EORTC pain CAT is currently available for ''experimental'' purposes.
Introduction
Adequate pain management requires reliable and precise assessment. As pain is a subjective symptom, assessment should be based on the patients' own perception of their pain [1, 2] . This can be achieved using patient-reported outcomes (PROs). PROs have typically been developed using classical methods like sum scoring of items. However, classical methods have some limitations. For example, all patients have to answer the same set of items for scores to be comparable. This means that patients often have to answer items that are not relevant for their level of pain and/or relevant items are missing since the total number of items has to be limited to keep the respondent burden at a reasonable level.
Using item response theory (IRT) [3, 4] for developing and scoring PROs overcomes some of these limitations. In particular, when a set of items has been calibrated (estimated) to an IRT model all scores based on any subset of the items are comparable. This unique feature means that a questionnaire can be adapted to the individual without compromising comparability across patients. This is utilized in computer adaptive testing (CAT) [5] . Based on the responses to the preceding items, a computer program evaluates which item should be asked next to obtain maximal information. In this way, the questionnaire is adapted to the individual, using the most informative items for each patient, thereby optimizing both the efficiency and the reliability of the assessment.
The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) is carrying out a large-scale project with the overall aim to improve the measurement of the health-related quality of life (HRQOL) domains included in the EORTC quality of life questionnaire, the QLQ-C30 [6] [7] [8] [9] [10] [11] [12] . This is achieved by developing a CAT measure for each domain in the EORTC QLQ-C30. This CAT instrument will be more precise, efficient and flexible than the EORTC QLQ-C30. The CAT item banks may be seen as the future version of the QLQ-C30. In time, it may be used in studies which would have used the QLQ-C30, but because of its increased precision and flexibility it may also be appropriate in additional settings, e.g., for monitoring individual patient progression.
The QLQ-C30 is one of the most widely used HRQOL questionnaires in cancer research [13, 14] . It consists of 30 items measuring 15 aspects of HRQOL. In the QLQ-C30, pain is measured with two items, one about pain intensity (including aspects of pain duration and frequency) (''Have you had pain?'') and one about pain interference (''Did pain interfere with your daily activities?'') [15] . Our conceptualization of pain was based among other things on the pain definitions by the International Association for the Study of Pain (IASP) and WHO's International Classification of Functioning, Disability and Health (ICF) [16, 17] . The QLQ-C30 items ask about pain in general without reference to specific parts of the body. Hence, our item development focused on asking about pain intensity and interference in general. We hypothesized that there would be a close link between pain intensity and pain interference: the more the pain, the more it interferes and vice versa, and in the QLQ-C30, the two pain items are thus combined into a single overall score. Therefore, in the CAT measure we also expect that pain intensity and pain interference can be viewed as two aspects of the overall, unidimensional construct of interest: pain. Both items have the response options ''not at all,'' ''a little,'' ''quite a bit'' and ''very much'' and a ''during the past week'' timeframe.
The aim is to develop a collection of items (a so-called item bank) for CAT measurement of the pain domain as measured with the QLQ-C30. The intention is to supplement the two pain items of the QLQ-C30 with new items, thereby increasing measurement precision and extending the range of pain intensity/interference that can be assessed.
Materials and methods
The general steps in the development of the item banks for the CAT version of the EORTC QLQ-C30 have been described in detail previously [7] [8] [9] [10] [11] [12] . The following summarizes each step of the development of the pain item bank.
Literature search
A literature search was conducted to identify existing instruments and items used to measure pain. This was not a systematic review, but rather aimed at acquiring sufficient information about pain measurement to form the basis for formulating new, relevant items. In the current case, the literature search was primarily based on an early version of the review of pain assessment tools conducted by the European Palliative Care Research Collaborative [18] . This list of items was supplemented with searches for additional pain items in the PROQOLID database (http://www.proqolid.org) and the EORTC QLG Item Bank [19] .
Formulation of items and expert evaluations
First, the list of items identified in step 1 was trimmed: items assessing aspects of pain other than intensity or interference and items with content that did not fit the ''QLQ-C30 item style'' (i.e., the response categories, time frame, etc.) were deleted. The resulting ''shortlist'' of items was used as inspiration for formulating new items measuring pain intensity and pain interference and fitting the item style of the QLQ-C30. We aimed at formulating items relevant for different levels of pain, thereby extending the range of pain that could be assessed. The item selection and formulation were carried out independently by two members of the project group. After each step, possible differences were discussed and a consensus was reached. The list of developed items was evaluated by international experts in pain measurement. The item list was revised based on these experts' evaluations.
Pretesting
The revised list of items was evaluated by a mixed, international sample of cancer patients. Before the interviews, the items were translated into the relevant languages by the Translation Office of the EORTC Quality of Life Department according to rigorous and well-established guidelines developed by the EORTC [20, 21] . The interviews followed the EORTC QLG guidelines for pretesting of items [22] and elucidated whether patients found some of the items difficult to answer, confusing, annoying, upsetting, intrusive, etc.
Field-testing and psychometric analyses
The items were field-tested in an international and heterogeneous sample of cancer patients. Eligible patients with a verified cancer diagnosis and age C18 years in contact with one of the participating oncology departments in Denmark, Italy, Sweden, Taiwan or UK were invited to participate. Patients were invited either by mail or when coming to the department. The sample included patients having different levels of pain, from ''no'' pain to ''severe'' pain. To ensure stable calibration of the IRT model, we aimed to collect at least 1000 responses [23] . The patients completed the new pain items together with the QLQ-C30. They also completed sociodemographic items and ''debriefing items'' to clarify whether certain items were inappropriate, ambiguous, etc.
The resulting dataset formed the basis for the final psychometric evaluations. These evaluations included:
Descriptive and basic statistical analyses
This included calculation of item mean scores, response frequencies, percent missing responses and correlations with the QLQ-C30 pain scale.
Evaluation of dimensionality and local dependence
As the QLQ-C30 assesses pain using a unidimensional scale, the aim was a unidimensional CAT measure of pain. We used factor analysis for ordinal variables using Mplus to explore the dimensionality of the item set [24, 25] . This included explorative evaluations of dimensionality based on eigenvalues (proportion of variance explained and scree plot [26] ) and more confirmatory methods evaluating the fit of unidimensional solutions including the QLQ-C30 pain items and as many of the candidate items as possible. Model fit was assessed by: root-mean-square error of approximation (RMSEA), the Tucker-Lewis Index (TLI) and the Comparative Fit Index (CFI). We used the rules of thumb that RMSEA \ 0.10 and TLI/CFI [ 0.90 indicate reasonable fit and TLI/CFI [ 0.95 indicates good fit [27] . Local independence (i.e., whether item responses are independent when controlling for the overall level of pain [4] ) was investigated using residual correlations. Correlations below 0.20 were regarded as indication of local independence [4, 28, 29] .
Calibration of the IRT model and evaluation of item fit
We used the generalized partial credit model (GPCM) [30] as the IRT model forming the basis for the CAT. This was calibrated using Parscale [23] . In the GPCM, each item has a slope parameter describing the item's ability to discriminate between subjects with different levels of pain, and a set of threshold parameters describing how likely it is to report problems on the item. Item fit was examined using Muraki's test [30] , bias estimates (average difference between expected and observed item responses) and the infit and outfit statistics, which are mean square residuals often used in Rasch fit analysis [10, [31] [32] [33] . Infit and outfit values between 0.7 and 1.3 are often regarded as acceptable [33] . Bias, infit and outfit were calculated using SAS v. 9.3 based on output from Parscale. We inspected the measurement precision across the continuum of the selected set of items by plotting the information function.
Test for differential item functioning (DIF)
DIF analysis explores whether items function differently for different groups of patients [34] . Using ordinal logistic regression methods [35, 36] , we tested for both nonuniform and uniform DIF with regard to gender, age, country, cancer site, cancer stage, current treatment, education, work and cohabitation (see Table 1 for the groupings used, and for age we used the groupings \40, 40-49, 50-59, 60-69, C70 years). Each item was entered as the outcome, and the group (DIF) variables were tested as independent variables controlling for the pain score estimated using the IRT model calibrated in the previous step. Significant DIF findings (p \ 0.001 and a regression coefficient [0.64/ change in R 2 -coefficient [0.035) [36, 37] were evaluated for their impact on the estimation of pain by comparing the pain scores obtained with an IRT model accounting for DIF (by estimating separate parameters across DIF groups for the item) with the scores obtained with the model from the previous step [9, 10, 38] . If only trivial differences in the scores were observed, the DIF did not seem to have practical consequences for pain estimation. All DIF analyses were done in SAS v. 9.3.
Evaluation of measurement properties
We evaluated the measurement precision of the resulting CAT pain measure using simulations of CAT administration based on the collected responses. We simulated CATs asking 1, 2,… up to all but 1 item, respectively, estimated the pain score based on these CATs, and compared them with the pain score based on all items. Using two-sample t test sizes, we evaluated the relative validity (RV) of these CATs as compared to the QLQ-C30 pain scale in detecting expected group differences [39] . We hypothesized that patients currently on treatment (chemotherapy or other cancer related treatment) would have significantly more pain than patients not on treatment and that patients with stage III or IV disease would have more pain than patients with stage I or II disease. In addition to these evaluations based on the observed data, we also evaluated the RV of the CATs based on simulated data. We simulated responses to the items based on pain scores sampled from normal distributions with different means. We compared groups of size N 1 = N 2 = 25, 50 and 100, respectively, and true effect sizes (ESs) of 0.2, 0.5 and 0.8, respectively. For each of these 3 9 3 = 9 possible conditions, we ran 2000 simulations. From the RVs, we estimated approximate savings in sample sizes using the CATs compared to the QLQ-C30 scale. For further details, please see Petersen el al. [11] .
The study was approved by the local ethical committees in the participating countries. Informed consent was obtained from each participating patient.
Results

Literature search
The review of pain assessment tools [18] resulted in a list of 231 items. This was supplemented with 65 additional pain items identified in PROQOLID and with 41 items identified in the EORTC QLG Item Bank, resulting in a total of 337 pain items.
Formulation of items and expert evaluations
We classified the identified items as measuring either pain intensity, interference or something else. Only items judged to measure pain intensity or interference were retained.
As the two QLQ-C30 items ask about pain in general, without reference to specific body parts, the items were further required to ask about pain in general or to be able to be reformulated to do so. In all, 140 items complied with these requirements. Next, we deleted redundant items and items that could not be reformulated into the QLQ-C30 item style. This resulted in the deletion of 113 items, leaving 27 items. These 27 items were used as inspiration for formulating new, unique items complying with the QLQ-C30 item style. This resulted in the formulation of 29 new candidate pain items. The 29 items were evaluated by 11 experts from Denmark, Germany, Italy, the Netherlands and the UK. The expert evaluations resulted in rewording of three items and deletion of four items: two because of redundancy, one because of ambiguity and one because of poor fit to the response options. The expert evaluations resulted in the addition of one new item. Hence, after these evaluations, the list consisted of 26 items.
Pretesting
A total of 31 patients were interviewed about the 26 candidate items and the two QLQ-C30 pain items. The patients came from Denmark, France and the UK and included both genders and 11 different cancer sites. Based on the interviews, we changed the wording of four items to make them clearer and seven items were deleted: five because of redundancy and two because several patients found them ambiguous/unclear. Hence, after these interviews the list consisted of 19 candidate items plus the two QLQ-C30 items, in all 21 pain items. Of these, 15 measured pain interference and six pain intensity.
Field-testing and psychometric analyses
We obtained responses from 1103 cancer patients. Patient characteristics are reported in Table 1 .
Descriptive and basic statistical analyses
The response rate per item was generally high (98.1-99.1 %). The average response across the items ranged from 0.33 to 0.86 on a 0-3 scale (with 0 = ''not at all''), indicating generally low pain levels in the sample, although about 250 patients (23 %) reported ''quite a bit'' or ''very much'' pain (item 21). Polychoric correlations between the new items and the QLQ-C30 pain scale ranged from 0.79 to 0.92.
Evaluation of dimensionality and local dependence
Exploratory eigenvalues analysis indicated that the first factor explained 85 % of the total variation. Subsequent factors all explained \4 % of the variation and all had eigenvalues \1. Factor loadings for a 1-factor solution ranged 0.76-0.91, with all but three [0.80. A unidimensional solution with the 21 items had RMSEA = 0.147, CFI = 0.977, TLI = 0.995. Given that all other indices indicated acceptable fit of a unidimensional solution for the 21 items, the somewhat large RMSEA may be explained by high reliability among the items [40] . All residual correlations between the 21 items were \0.10, i.e., no indications of local dependence. Therefore, all 21 items were retained.
Calibration of the IRT model and evaluation of item fit
Our initial attempts to fit an IRT model to the 21 items failed; either the estimation procedure could not converge or it resulted in unreliable, extreme estimates of some parameters. Inspections of item crosstabs and correlations revealed that, although residual correlations did not indicate local dependence, several items were highly correlated (polychoric correlations [0.9). The main reason was that 38 % of the sample had responded ''not at all'' (i.e., no pain) to all items. The responses from these patients are clearly mutually highly predictable/locally dependent. Among patients responding ''not at all'' to the two original QLQ-C30 pain items (44 % of the sample), 85 % had responded ''not at all'' to all items, and their average score was 0.7 on a 0-100 scored sum scale consisting of the 21 items. Hence, asking these ''no pain'' patients several pain items would have very little relevance from either a clinical or a measurement perspective. Therefore, we decided to exclude the patients responding ''not at all'' to the two QLQ-C30 pain items from the IRT analyses, reducing the sample to 617 (see Table 1 ). Doing this, it was possible to fit an IRT model. Evaluations of item fit and DIF were conducted on both the full and reduced samples of patients. Generally, evaluations on the two samples resulted in similar findings and conclusions. The evaluations of item fit indicated that five items had poor fit to the model and/or were locally dependent with some of the other items and were therefore deleted. Fit statistics for the remaining 16 items (based on the reduced sample) are shown in Table 2 . All item fit tests had p [ 0.04 (and except for item 11 all [0.10). Bias estimates were all very close to 0 (\0.1). The infit statistics ranged 0.76-1.07 and the outfit statistics 0.71-1.03, all within the acceptable range. The fit statistics were similar in the full sample, with the exception that the outfits were generally lower, often below 0.7 reflecting the highly predictable response patterns of the ''no pain'' patients. As ''redundancy'' for this special subsample of patients is expected and unavoidable, the low outfits do not seem problematic (note that the infits are all [0.7). Hence, the fit of these 16 items was deemed acceptable.
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Test for DIF
There was no significant DIF with regard to age, gender, cancer stage, education or cohabitation. Items 4, 6, 7 and 21 showed significant DIF between countries, and item 7 also showed DIF between patients on and off treatment. There was significant DIF between cancer sites for item 16 and between working and retired patients for item 18. We evaluated the possible impact of these DIF findings for the estimation of pain both when using all items to estimate pain and when only using the DIF item of focus. Pain scores based on a model accounting for DIF (separate item parameters in the DIF groups) and the model not assuming DIF (same parameters in all subgroups) correlated all [0.99 and differed on average less than 0.3 (about five points on a 0-100 scale). Hence, these evaluations indicated that the possible DIF would have only negligible impact on the estimation of pain, i.e., the possible DIF did not result in biased pain scores. Therefore, no items were deleted because of DIF. Parameter estimates of the final 16 items are shown in Table 2 . Except for item 21, all locations were [0, indicating that the items were mainly relevant for patients with at least a little pain. This is also evident from Fig. 1 which shows the total information when using all 16 items and the two QLQ-C30 items only, respectively. Considering information = 10 (corresponding to a reliability of 0.90) as a threshold for reliable measurement, the total item bank provided reliable measurement from about -1.0 to 2.5 (3.5 standard deviation units). Asking the two QLQ-C30 items only provides markedly less information for all levels of pain except for patients with ''no pain'' (lower extreme). Hence, the two QLQ-C30 items may be particularly useful for screening for patients with ''no pain.'' Redoing the factor analyses for the final 16 items on the subsample of ''pain'' patients confirmed the previous findings of unidimensionality, one factor explained about three-quarters of the variation and all items had loadings C0.78. Figure 2 shows that for CATs of all lengths, the median pain score was very close to the median score based on all items (all deviations \0.06). For about 50 % of the patients, the scores obtained using only one item deviated [0.4 from the score based on all items, while when asking five items only about 10 % had scores deviating [0.4. As the score based on all items ranged from -2.2 to 3.0, 0.4 is less than 8 % of the possible score range, i.e., similar to eight points on a 0-100 scale. Scores based on one item correlated 0.77 with the scores based on all items, with two items the correlation was 0.88, while using three or more items the correlations were [0.92 (results not shown). Figure 3 summarizes the results of the known-groups comparisons. The comparisons based on the observed data confirmed the hypothesized group differences and indicated that CAT measurement asking four or more items reduced the sample size requirements by about 20-25 % without loss of power compared to using the original QLQ-C30 pain scale. The estimated reduction in required sample size/increased power was somewhat lower based on the simulated data. These simulations indicated that, regardless of the length of the CAT, sample sizes may be reduced by less than 15 %, and at least seven items may be required for a reduction [10 %.
Evaluation of measurement properties
Discussion
The EORTC QLG is developing a CAT measurement system for assessing the HRQOL domains included in the widely used EORTC QLQ-C30 questionnaire. The EORTC CAT development process can be divided into four phases: literature search, item construction, pretesting and fieldtesting. These phases are closely related to the phases of EORTC QLG module development [22] . Here we have reported the results of the development of the pain item bank.
The literature search yielded valuable insights into how pain may be measured. This was a useful inspiration for formulating items measuring pain in the ''EORTC QLQ-C30 way.'' Note that the literature search was not, and was not intended to be, an exhaustive review of all available pain items, but was intended to identify the different ways pain items may be formulated to cover different aspects and levels of pain. With the identification of over 300 pain items, we feel confident that all relevant item variants were covered sufficiently. From the literature search and item formulation, it was apparent that, with our requirements for item formatting (response options), it was difficult to construct a large number of relevant and distinct items, particularly about pain intensity. Hence, only four of the 16 items in the final item bank ask directly about pain intensity. The remaining items measure pain interference. But clearly, these items also provide valuable insight into the level of pain (the more the pain interfered, the more severe it was likely to have been). The psychometric analysis also indicated that the intensity and interference items together formed a unidimensional construct. Still, it may be preferable to avoid asking only interference items. In this case, the CAT can be programmed to always include both intensity and interference items. This principle can be extended to ensure coverage of other aspects if relevant (e.g., different aspects of interference).
Basing the CAT on an established HRQOL instrument, the QLQ-C30, has several advantages including backward compatibility with a very large literature, measurement of well-validated HRQOL domains and simplified conceptual work as we did not have to establish a whole new framework of measurement. However, this approach limited the number of relevant items that could be constructed. Still, we have extended the QLQ-C30 pain scale from two to 16 items, a considerable expansion.
The expert and patient evaluations were invaluable in identifying problematic items and in optimizing item formulation. The patient perspective was particularly important in ensuring that the items are appropriate and comprehensible for cancer patients. We deleted seven of the candidate items because of redundancy or other problems pointed out by patients during the pretesting. The psychometric analyses indicated that 16 items could be retained in a unidimensional item bank. IRT calibration and evaluations generally showed good fit of these items. We found some indications of DIF. However, evaluations of the DIF indicated that these had no significant impact on the estimation of pain. Hence, we consider the items to be appropriate for general use in cancer patients, regardless of gender, age, cancer site, etc. Further, as the items have been developed, calibrated and evaluated in an international setting, the CAT measure will be appropriate for international use. As with the QLQ-C30, the CAT measure is intended to be applicable and available in a multitude of languages.
To be able to estimate the IRT model, we had to exclude a substantial proportion of patients (44 % of our sample) who had responded ''not at all'' to the two QLQ-C30 pain items. Using less than 60 % of our sample for the IRT calibration is a clear limitation of the study. However, as the responses from the excluded patients were very similar (''not at all'' to all/almost all items), they provided very limited information on the relative item locations and discriminations (slopes). That is, we likely excluded far less than 44 % of the total information in the sample with this strategy.
The excluded patients generally had no or very little pain, and hence, detailed questioning about their level of pain would have little relevance from either a clinical or a measurement perspective. Further, although evaluations generally indicated that the items were appropriate to use for both patients with and without pain, it is apparent, e.g., from the information function ( Fig. 1) , that the items are primarily relevant and informative for patients who have at least a little pain. Therefore, it may be most appropriate to first screen patients for pain using the two QLQ-C30 pain items. Only patients who report at least ''a little'' pain on one of these two items may then proceed to complete additional CAT items.
In general, the CAT pain items appeared to be efficient and precise. For example, pain scores based on three items correlated 0.93 with the scores based on all 16 items. However, as the evaluations were based on the data used to calibrate the IRT model, the efficiency and precision may have been overestimated. We intend to conduct additional studies to examine these issues in independent data.
The results of the known-groups comparisons based on observed data indicated that, if four or more items are asked, sample sizes may be reduced by 20-25 % without loss of power as compared to the QLQ-C30. The simulations on the other hand indicated that this reduction would be at most 10-15 %. Hence, both analyses indicate increased power using the new measure, but it is inconclusive what the actual gain may be and this will probably vary across studies. Additional, detailed evaluations of the power of the CAT measure in independent data are needed and are planned.
The EORTC CAT pain measure includes the two QLQ-C30 pain items, and all new items have been constructed and selected to measure the same pain aspects as the C30 items and to have the same item format. The purpose of this was to obtain a homogenous and user-friendly measure that will measure the same concept as the QLQ-C30 pain scale. Based on the strong associations between the original and new items, it seems reasonable to assume that the new measure is also valid. However, it would still be interesting and relevant to compare the EORTC CAT pain instrument with external, validated pain measures, as well as to alternative item formats for measuring pain, e.g., 0-10 numerical rating scale. This will elucidate the validity of the CAT and give valuable information on measurement precision, patient preferences, etc., of the CAT instrument compared to other instruments. Furthermore, it will allow the construction of linking [41, 42] (also called crosswalking [43] ) between the EORTC pain measure and other established pain measures.
Although the development of the EORTC CAT has not yet been completed, the current version may be used for ''experimental'' purposes. By ''experimental'' it is meant that until the final, validated version of the EORTC CAT is released, it should be used in parallel with the EORTC QLQ-C30. If access to computer or other electronic device for running CAT is not available, one may still take advantage of the item banks to construct short forms, i.e., study-specific (paper) questionnaires with a fixed set of items selected for optimal measurement in the specific study. For more information on the preliminary use of the EORTC CAT and short forms, please visit http://groups. eortc.be/qol/eortc-cat.
In conclusion, we have developed an item bank of 16 items for CAT measurement of pain. This CAT measure will be backward compatible with the QLQ-C30 and hence Fig. 3 Average relative validity (RV) and relative required sample size using CAT measurement compared to using the QLQ-C30 sum scale based on observed and simulated data, respectively. For both RV and sample size, the figure shows the ratio of using the CAT compared to using the QLQ-C30 sum scale. For example, using a CAT with four items, the observed data indicate that the validity of the CAT is 1.13 that of the C30 scale resulting in that only 0.78 (78 %) of a sample size used with the C30 scale is required using the CAT to obtain the same power Qual Life Res (2016) 25:1- 11 9 with the many studies that have used this questionnaire. The item bank showed good psychometric properties and high measurement precision for patients with some degree of pain. It is for these patients that more detailed information would be particularly useful. Evaluations of power were somewhat ambiguous, but indicated that sample sizes may be reduced up to 25 % without loss of power, compared to the QLQ-C30. However, these measurement properties should be validated with new data before drawing any final conclusions. Even though the item bank is targeted to cancer patients, the items are formulated in general non-cancerspecific terms and hence may be applied in other patient populations (and the general population) as well.
